(Nasdaq: SXTP) Makes An Approx 156% Early Move Surpassing Several Key Indicators

*Sponsored by 60 Degrees Pharmaceuticals, Inc. Market Crux Exclusive! 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) Just Announced As Our Next Potential Breakout Idea… And Here’s Why… Ultra-Low Float: Only 1.5M shares in the float, sets the stage for significant swing potential if demand begins to shift. Insider Confidence: CEO insider purchases highlight strong belief in the company’s future and growth prospects. Analyst Target: A $3.40 target suggests 165% upside potential from yesterday’s $1.28 open. (On 1/07/2025) Momentum Potential: An approximate 254% move in six weeks could signal a growing public interest. Strong Intellectual Property: Over 40 patents, including three Orange Book-listed patents, provide market exclusivity and innovation strength. FDA-Approved Product: Addresses a $50–$70M U.S. malaria market and is commercially available. Expanding Pipeline: Pivotal trials for tick-borne diseases and chronic illnesses position the company in key emerging markets. Consider adding 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) to your watchlist this week… January 8, 2025 Dear Reader, When a company makes strides toward solving a critical medical challenge, it often sparks momentum that can’t be ignored. Today, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) moved approximately 156% in the pre-market, from $1.405 to $3.60 (according to Nasdaq), driven by the announcement of its first patient enrollment in an expanded access clinical study for tafenoquine. This study is a major step forward in addressing persistent babesiosis, a disease with rising incidence rates and limited treatment options.  Breaking through key moving averages, including the 200-day (2.0483), (SXTP) is gaining both technical and clinical momentum.  With prior studies showing an 80% cure rate, tafenoquine could address a growing market projected to exceed 400k patients by 2035.  The progress is real, and 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is leading the way. Now, if you missed my coverage from earlier today, keep reading to see why we’re so excited about this one. Introducing 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP), a leader in one of our favorite sectors and a name that turned heads before.  The last time we covered (SXTP) it moved approximately 60% in under 24 hours. Here’s what has us locked in this time: An ultra-low float of only 1.5M shares, setting the stage for potential swings.  Analyst target suggests 165% potential upside target. An approximate 254% move in six weeks, could suggest the public is starting to catch on. Strong intellectual property portfolio with over 40 patents. Insider buying with CEO recently buying shares according to Benzinga. Triggering 15 Bullish Signals on TradingView’s technical analysis tool. We called it before, and this time, we’re calling it again—60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is now at the top of our watchlist for Wednesday morning. Let’s dive into why 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is #1 on our watchlist this morning.  In the high-stakes world of pharmaceutical innovation, few companies dare to challenge the norms with as much confidence and expertise as 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP).  Focused on addressing critical unmet needs in infectious disease treatment, 60P has built a robust portfolio that combines scientific ingenuity with a relentless drive for results.  From malaria prevention to tackling tick-borne illnesses like babesiosis, this company is setting the gold standard for innovation, commercial growth, and global impact. A Game-Changer in Malaria Prevention ARAKODA® (tafenoquine), 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)’s flagship product, is a revolutionary antimalarial therapy that earned FDA approval in 2018 and became commercially available the following year.  Unlike other treatments, ARAKODA® provides complete protection against all stages of malaria with a convenient weekly dosing schedule—no resistance, no hassle.  Its unique attributes, including broad-spectrum activity, have earned recommendations from the CDC and cemented its reputation as the top choice for malaria prophylaxis. With a $50–$70 Mln U.S. market for malaria prevention alone, ARAKODA® has already established a foothold in a critical space, showing consistent sales growth.  And let’s not overlook the bigger picture: a global burden of 249 Mln malaria cases annually underscores the dire need for solutions like ARAKODA®. Expanding Horizons: Tackling Tick-Borne Diseases Not content with its success in malaria, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is charging ahead in the treatment of babesiosis, a tick-borne disease on the rise in the U.S.  The company has launched pivotal trials for acute babesiosis and plans to address chronic cases next.  FDA orphan status for tafenoquine highlights its potential as the only game in town for a disease where existing treatments lack efficacy. Babesiosis isn’t just a public health issue—it’s a market with significant potential. With up to 1 Mln chronic cases in the U.S. and growing acute incidence rates, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is positioning itself to dominate this emerging space, potentially expanding its patient reach to over 2 Mln. Strong Intellectual Property Portfolio A critical driver of 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)’s success is its robust and expanding intellectual property portfolio.  The company holds three Orange Book-listed patents for tafenoquine, protecting its malaria prevention innovations until 2035.  With 42 additional patents filed, pending, or optioned across multiple therapeutic areas—including tick-borne diseases and respiratory viruses—60P is playing a long game, ensuring market exclusivity and driving future growth. A Leadership Team That Delivers Behind this powerhouse is a leadership team with unmatched experience and credentials. CEO Geoffrey Dow is a 20-year veteran in tropical disease product development, having spearheaded the regulatory approval of ARAKODA®.  Chief Medical Officer Bryan Smith, with 30+ years of clinical expertise, brings unparalleled insight into pharmacovigilance and regulatory strategy.  And let’s not forget Chief Commercial Officer Kristen Landon, who has launched more than a dozen blockbuster brands, driving revenues well into nine figures. This team isn’t just talking the talk—they’re walking the walk, executing on ambitious plans to scale commercial operations and meet aggressive pro-fit-ability targets by Q4 2026. Evolving Strategies for Commercial Growth 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)’s commercial strategy for ARAKODA® is razor-sharp: differentiate it from generic competitors with a compelling value story, expand its use among healthcare providers, and reduce access barriers through co-pay assistance programs.  This targeted approach has already shown results, with organic sales growth reflecting increased awareness among prescribers in the Lyme disease community. And it doesn’t stop there.  The company’s forward-looking pipeline includes Celgosivir, targeting dengue and respiratory viruses, and an exploratory program for canine babesiosis, hinting at diversification into veterinary markets. Fiscal Momentum and Milestones Ahead The numbers don’t lie. Recent rounds have injected over $5.9M into 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)’s coffers, enabling critical funding in commercialization and clinical development.  With three babesiosis trials underway, the company is poised to deliver interim results by early 2026—just in time to accelerate its push toward pro-fit-ability. Upcoming potential catalysts include sales growth milestones, new product development collaborations, and regulatory submissions.  If history is any guide, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) isn’t just checking boxes; it’s carving out its place in the biotech space. The Bottom Line 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is more than a pharma company—it’s a force to be reckoned with in the fight against infectious diseases.  With groundbreaking products, a visionary leadership team, and an aggressive roadmap for growth, (SXTP) is redefining what’s possible in this space.  For those watching closely, one thing is clear: this company doesn’t just participate—it dominates. 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is drawing attention with several potential catalysts that could help drive its momentum.  With a razor-thin float of only 1.5M shares, the company is positioned for potential market movements.  Recent insider purchases by the CEO reflect confidence in its direction, while a 165% upside target points to notable growth potential. The company has recently witnessed an approximate 254% move in six weeks, which could be an indicator of growing market interest.  As of midday, yesterday (1/7/2025), (SXTP) was triggering 15 Bullish Signals on TradingView’s technical analysis tool using the 15 minute time-frame.  Coupled with a robust intellectual property portfolio of over 40 patents, the company is positioning itself to advance its efforts in addressing unmet medical needs.  These elements create a compelling case for keeping an eye on this emerging biotech player. Recent Headlines 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) and Tufts Medical Center have signed a Patent License Agreement aimed at advancing the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. This collaboration marks a pivotal step in addressing an urgent need for new therapies to combat this tick-borne disease, which affects thousands annually. Key points of the agreement include: Joint Patent Ownership: Co-ownership of intellectual property related to tafenoquine for babesiosis, with (SXTP) leading patent prosecution globally. Exclusive Commercialization Rights: (SXTP) retains worldwide rights to develop and market tafenoquine for babesiosis. Revenue Sharing: Tufts MC will earn royalties from net sales of tafenoquine-based products targeting babesiosis. Research Advancement: Tufts MC maintains a royalty-free license for research purposes to drive continued innovation. Focused Development: (SXTP) is committed to advancing tafenoquine beyond its current use for malaria to meet the needs of babesiosis patients. This agreement builds on promising research, ongoing clinical trials, and a growing understanding of tafenoquine’s potential for treating babesiosis. The trials, conducted at prominent institutions including Tufts MC and Yale, aim to determine the efficacy in addressing severe cases of this parasitic disease.  If successful, tafenoquine could become the first prophylactic treatment for babesiosis, addressing a critical gap in care. CEO Geoff Dow, PhD of 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP)  stated that this collaboration underscores the shared confidence in tafenoquine’s potential to meet a growing unmet medical need and offer solutions for both treatment and prevention of babesiosis. 7 Reasons Why 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is #1 On Our Watchlist Tomorrow… 1. Razor-Thin Float: With just 1.5M shares in the float, the stage is set for the potential of big swings if demand begins to change.  2. Insider Confidence: Recent insider purchases by the CEO signal strong belief in the company’s future, showcasing leadership's commitment to growth. 3. Analyst Target Highlights Growth Potential: Analyst’s $3.40 target suggests a 165% upside potential from yesterday’s $1.28 open on 1/07/2025. 4. Building Momentum: An approximate 254% move over six weeks could suggest the public is starting to catch on to 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP). 5. Strong Intellectual Property: Boasting over 40 patents, including three Orange Book-listed patents for its flagship malaria treatment, the company has built a solid foundation for innovation and market exclusivity. 6. FDA-Approved Product: The company’s flagship product, ARAKODA®, is already FDA-approved and commercially available, addressing a $50–$70M U.S. malaria prevention market while targeting a global health crisis. 7. Expanding Pipeline: The company’s ongoing pivotal trials for tick-borne disease treatments and plans for addressing chronic illnesses position it as a key player in emerging medical markets. Consider Adding 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) to Your Radar This Week… 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) has all the hallmarks of a biotech worth paying attention to. With an ultra-low float of just 1.5M shares, the potential for significant market movement is clear.  Insider confidence is evident with recent CEO purchases, while Lucas Ward, an analyst at Ascendiant Capital Markets, recently set a $3.40 target on 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) which suggests 165% upside potential underscores the growth potential from today’s opening level of around $1.28. The company’s potential momentum appears to be already building, with an approximate 254% move in six weeks, signaling what could be a growing public interest.  Its robust intellectual property portfolio of over 40 patents, combined with the FDA-approved ARAKODA®, places it in a strong position to capitalize on the $50–$70M U.S. malaria prevention market and address critical global health challenges. Looking ahead, 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) is not just relying on its success in malaria; its expanding pipeline targeting tick-borne diseases and chronic illnesses demonstrates its commitment to innovation and long-term growth.  This is a company with the vision, leadership, and foundation to make a meaningful impact in the biotech sector. Remember, (SXTP) only has 1.5M shares listed in the public float, with a recent analyst target suggesting 165% in potential upside.  As of midday, yesterday (1/07/2025), 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) was triggering 15 Bullish Signals, including the momentum indicator. We’ll have all eyes on (SXTP) this morning so keep a lookout for my next update. The last time we covered (SXTP) it moved approximately 60% in under 24 hours. This morning 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP) moved approximately 156% in the pre-market. In case you missed it the first time, this little-known biotech is at the top of our watchlist again.  Have you pulled up (SXTP) yet? Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired by TD Media LLC for a period beginning on 01/07/2025 and ending on 01/10/2025 to publicly disseminate information about (SXTP:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”) to disseminate information about (SXTP:US) via digital communications. To date, including under the previously described agreement, Headline Media LLC has been paid seventeen thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from 60 Degrees Pharmaceuticals Inc., the issuer of (SXTP:US).Neither Headline Media LLC, TD Media LLC or their members own shares of (SXTP:US). Please see important disclosure information here: https://marketcrux.com/disclosure/sxtp/

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice